Anzeige
Mehr »
Login
Sonntag, 28.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Fokus auf Nurexone: High-Level Biotech im Pennystock-Kleid!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
285 Leser
Artikel bewerten:
(1)

ADM Tronics Unlimited, Inc.: ADM Tronics Reports Second Quarter of Fiscal Year 2024 Results

NORTHVALE, NJ / ACCESSWIRE / November 14, 2023 / ADM Tronics Unlimited, Inc. (OTCQB:ADMT), a technology-based developer and manufacturer of innovative technologies and products, announces results for its second fiscal quarter ended September 30, 2023 of Fiscal Year 2024.

During the period ended September 30, 2023 ADMT devoted a significant portion of its engineering and manufacturing resources towards the finalization of the Vet-Sonotron, ADMT's innovative non-invasive veterinary therapy device for the treatment of pain in small animals and for equine. With the dedication of resources to the Vet-Sonotron development and preparations for production, ADMT had reduced revenues during the period from its segments.

Revenues for the six months ended September 30, 2023 were 1,516,821 as compared to $2,061,676 for the six months ended September 30, 2022, a decrease of 26%. The decrease in revenues was primarily due to the use of resources towards the development of ADMT's Vet-Sonotron technology. Loss from operations for the six months ended September 30, 2023 was $365,446 as compared to income of $68,267 for the same period last year.

Revenues for the three months ended September 30, 2023 were $754,132 as compared to $1,140,268 for the three months ended September 30, 2022, a decrease of 34%. The decrease in revenues was primarily due to the use of resources towards the development of ADMT's Vet-Sonotron technology. Loss from operations for the three months ended September 30, 2023 was $227,620 as compared to income of $102,892 for the same period last year.

Complete financial results are available in the Company's Quarterly Report on Form 10Q for September 30, 2022, available at www.sec.gov.

Financial Highlights

Three Months Ended Six Months Ended

September 30, September 30,

2023 2022 2023 2022
Net revenues
$754,132 $1,140,268 $1,516,821 $2,061,676

Cost of sales
$547,980 $582,235 $985,527 $1,120,584

Gross Profit
$206,152 $558,033 $531,294 $941,092

Total Operating expenses
$433,802 $455,141 $896,740 $872,825

Income (loss) from operations
$(227,650) $102,892 $(365,446) $68,267

Total other income (expense)
$(455) $(2,849) $5,080 $(6,890)

Net income (loss)
$(228,105) $100,043 $(360,366) $61,377

Basic and diluted per common share
$(0.00) $0.00 $(0.01) $0.00
Weighted average shares of common stock outstanding - basic and diluted
67,588,504 67,588,504 67,588,504 67,588,504

About ADMT

ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three areas of activity: Proprietary Electronic Medical Devices; Design, Engineering, Regulatory and Manufacturing Services; and, Eco-Friendly, Safe, Water-Based Formulations. The Company's headquarters, laboratories, FDA-Registered medical device and manufacturing operations are located in Northvale, NJ. ADMT's multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, for the research, development and commercialization of diversified technologies. Additional information is available at admtronics.com

Except for historical information contained herein, the matters set forth in this news release are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT's filings with the SEC, news releases and other communications. The Company assumes no obligation to update the information contained in this news release.

SOURCE: ADM Tronics Unlimited Inc.

View source version on accesswire.com:
https://www.accesswire.com/803474/adm-tronics-reports-second-quarter-of-fiscal-year-2024-results

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2023 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.